ClinicalTrials.gg
Not yet recruitingNCT06007014Updated Sep 13, 2023

Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes

An interventional study of Chiglitazar sodium and Chiglitazar placebo in Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients, Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect and 128 Patients Were Randomly Assigned 1:1, sponsored by Yanbing Li. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Yanbing Li · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
451st of 769
128 · median 192
Started
2023
with 61 others
No phase
195 of 913
55 open now
Primary completion
2025-10
later than 45 of 228 live
Registered
599th of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 451st largest by planned enrollment of the 769 interventional ones that give a count, is one of 62 that started in 2023, is one of 195 with no phase, reaches primary completion later than 45 of the 228 other live ones, and was the 599th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the Efficacy and Safety of Chiglitazar Added to Patients with type 2 diabetes who do not respond well to metformin combined with insulin glargine. The main question it aims to answer are:

  • T2DM patients still cannot effectively control their blood sugar with the combination of insulin and metformin. The combination of follow-up treatment and hypoglycemic drugs is worth exploring, and it is necessary to explore and confirm the combination of effective and safe drugs for insulin resistance on the basis of the above treatment plans.

Participants will be asked to receive either Chiglitazar or placebo in addition to metformin and insulin glargine 18 weeks.

Researchers will compare placebo groups to see if the effective effect and safety indicators of Chiglitazar for reducing insulin dosage, lowering blood sugar, regulating blood lipids.

Read the detailed description

T2DM patients using insulin combined with metformin dual therapy regimen, still can not have effective control of blood sugar, the combination of follow-up treatment and hypoglycemic drugs is worth exploring, and it is necessary to base on the above treatment plans to explore and confirm the treatment of effective and safe drugs for insulin resistance. This study investigated the efficacy and safety of metformin combined with insulin glargine in the treatment of type 2 diabetes mellitus (T2DM) in patients who still have poor hypoglycemic effect, plus Chiglitazar 48mg/ day for 18 weeks.

A total of 128 patients were expected to be included, and were randomly assigned 1:1 to the combination of metformin and insulin glargine combined with Chiglitazar sodium tablet 48mg/ day group. Metformin and insulin glargine combined with placebo group.

03

Conditions studied

  • Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients
  • Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect
  • 128 Patients Were Randomly Assigned 1:1
  • Metformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day Group
  • Metformin and Insulin Glargine Combined With Placebo Group
  • InvestigatorInitiate Trial
  • Changes in HbA1C From Baseline at 18 Weeks of Treatment

Keywords

  • Chiglitazar
  • T2DM
  • Randomised
  • Double-blind
  • Placebo Parallel Controlled
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.In accordance with the World Health Organization (WHO) issued in 1999 diabetes diagnostic criteriaType 2 diabetes mellitus (T2DM);
    1. Male or female patients ≥18 years old;
  • 3, ≥18.5 Kg/m2, \< 35 Kg/m2;
  • 4, Glycosylated () > 7.5%; ≤10.5%;
  • 5, Stable dose (insulin daily therapeutic dose change within ±20%) of glycerine or DI The therapeutic dose of Terterigu or NPH basal insulin is ≥0.25IU/kg/ day/or 20IU/ day;
  • 6, Stable basic insulin treatment combined with metformin (metformin dose ≥1000mg/Days or maximum tolerated dose) ≥3 months;
    1. Voluntarily sign and agree to be randomly assigned to any experimental group.

Exclusion criteria

Exclusion Criteria:

  • 1, Type 1 diabetes or specific type diabetes;
    1. Fasting blood glucose (FPG) exceeding 13.3 mmol/L (240 mg/dL);
  • 3, hypertension [that is, on the basis of improving lifestyle, the application of a reasonable and tolerable sufficient amount of 3 or more antihypertensive drugs (including diuretics) for more than 1 month still does not reach the standard, or take 4 or more antihypertensive drugs to effectively control blood pressure];
    1. Triglyceride (TG) > 500 mg /dL (5.65 mmol/L);
  • 5, is taking or in the last 1 month has taken fibrate drug treatment;
  • 6, lower limb edema or general edema;
    1. Experienced 3 or more episodes of severe hypoglycemia and/or unintentional hypoglycemia in the 6 months prior to screening;
    1. A definite diagnosis of osteoporosis or any other known bone disease;
    1. History of diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome, lactic acidosis and other acute complications of diabetes;
    1. Severe microvascular complications (proliferative retinopathy; Urinary albumin/creatinine ratio > 300 mg/g; Marked peripheral neuropathy, etc.);
    1. Large vascular lesions leading to hospital admission within 6 months before inclusion;
  • 12, The (NYHA) defines congestive heart failure as grade III or IV
  • 13, significant liver and kidney dysfunction and systemic disease (significant liver dysfunction is defined as > 2.5 times the and/or ALT> 2.5 times the upper limit of normal and/or total > 1.5 times the upper limit of normal value; Renal dysfunction was defined as moderate to severe renal insufficiency (\<60 ml/ (min*1.73m2)).
    1. Use of other hypoglycemic agents not specified in the inclusion criteria (thiazolidinediones, GLP-1RA, premixed or fast-acting insulin) in the current or 3 months prior to screening, with the exception of short-term treatment with additional insulin (a total of 7 days or less) for complications;
  • 15, pregnant or lactating women, women of childbearing age who are unable or unwilling to take adequate ;
    1. Participating in clinical trials of other drugs or medical devices during or within 3 months prior to screening;
    1. The investigator considers it inappropriate to participate in this clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Metformin and insulin glargine combined with sitaglitat sodium tablets 48mg/ day group;

    Drug: Chiglitazar sodium

  • Placebo comparator
    Placebo group

    Metformin and insulin glargine combined with placebo group

    Drug: Chiglitazar placebo

Interventions

  • DrugChiglitazarStudies of ChiglitazarChiglitazar pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    tablets 48mg/ day administered for 18 weeks

  • DrugChiglitazar placebo

    tablets 48mg/ day administered for 18 weeks

06

What researchers measure

Primary outcomes

  1. HbA1C

    Changes in HbA1C from baseline

    Time frame: 18 weeks of treatment

Secondary outcomes

  1. Insulin

    Changes in the daily dose of insulin from baseline

    Time frame: 6 weeks and 18 weeks of treatment

  2. Triglyceride

    Changes in the daily dose of triglyceride from baseline

    Time frame: 18 weeks of treatment

  3. Fasting blood glucose

    Changes in the daily dose of fasting blood glucose from baseline

    Time frame: 6 weeks and 18 weeks of treatment

  4. Fasting C-Peptide

    Changes in the daily dose of fasting C-Peptide from baseline

    Time frame: 18 weeks of treatment

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Oct 2025, 23 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 23 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 23, 2023
StartEst.
Oct 31, 2023
Primary completionEst.
Oct 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06007014
Lead sponsor
Yanbing Li
Responsible party
Yanbing Li (Professor, Sun Yat-sen University) — Sponsor-investigator
First posted
Aug 23, 2023
Start date
Oct 31, 2023 (estimated)
Primary completion
Oct 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Sep 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiglitazar

Start the discussion